Abstract：Objective: To investigate the relationship between serum levels of Visfatin, high mobility group protein B1 (HMGB1) and Ghrelin and disease severity and prognosis in patients with acute pancreatitis (AP). Methods: Totally 198 AP patients in the hospital were selected from July 2019 to July 2023. According to the revised Atlanta classification (RAC), mild patients were included in mild group (n=113), and moderately severe and severe patients were enrolled as moderate-to-severe group (n=85). The enrolled patients were classified into survival group (n=182) and death group (n=16) by means of 28-day survival status. The differences in clinical data and serum levels of Visfatin, HMGB1 and Ghrelin were compared among different groups. Correlation analysis was used to assess the relationship between serum Visfatin, HMGB1 and Ghrelin levels and modified CT severity index (MCTSI), acute physiological and chronic health evaluation score (APACHE II) and determinant-based classification (DBC) in AP patients. Logistic regression analysis was used to analyze the factors leading to poor prognosis in patients with acute pancreatitis. Receiver operating characteristic curve (ROC) was used to evaluate the value of serum Visfatin, HMGB1 and Ghrelin on predicting poor prognosis in patients with acute pancreatitis. Results: MCTSI score, APACHE II score and levels of serum Visfatin, HMGB1 and Ghrelin in mild group were lower than those in moderate-to-severe group (P<0.05). MCTSI score, APACHE II score, serum Visfatin, HMGB1 and Ghrelin in survival group were lower while the proportion of DBC mild disease was higher than that in death group (P<0.05). Serum Visfatin, HMGB1 and Ghrelin in AP patients were proportional to MCTSI score, APACHE II score and DBC grading (P<0.05). High serum Visfatin, HMGB1 and Ghrelin were independent risk factors for poor prognosis in AP patients (P<0.05). The combined detection of serum Visfatin, HMGB1 and Ghrelin predicted the prognosis of AP patients with an AUC of 0.892, which was better than that of serum Visfatin alone (P<0.05). Conclusion: Serum Visfatin, HMGB1 and Ghrelin are closely related to the disease severity and prognosis in AP patients. The higher serum Visfatin, HMGB1 and Ghrelin, the more severe the disease and the higher the risk of 28-day death, and the combination of the three indicators can better evaluate the prognosis in AP patients.
殷若哲, 周阳, 潘龙飞. 急性胰腺炎患者血清Visfatin HMGB1 Ghrelin水平与病情严重程度及预后的关系研究[J]. 河北医学, 2025, 31(10): 1664-1670.
YIN Ruozhe, ZHOU Yang, PAN Longfei. Relationship between Serum Visfatin HMGB1 and Ghrelin Levels and the Severity and Prognosis of Patients with Acute Pancreatitis. HeBei Med, 2025, 31(10): 1664-1670.
[1] 黄婧磊,柴长鹏,王陈宇,等.2000-2030年中国胰腺炎疾病负担趋势分析与预测[J].兰州大学学报(医学版),2024,50(3):56-61. [2] Yu X,Zhang N,Wu J,et al.Predictive value of adipokines for the severity of acute pancreatitis: a meta-analysis[J].BMC Gastroenterol,2024,24(1):32. [3] Sirtl S,Beyer G,Mayerle J.Clinical and translational markers of severity and prognosis in chronic pancreatitis[J].Curr Opin Gastroenterol,2022,38(5):501-508. [4] Iwai N,Sakagami J,Kagawa K.Gastrointestinal: acute pancreatitis related to a ghrelin receptor agonist[J].Gastroenterol Hepatol,2022,37(8):1473. [5] 李蓉洁,彭依,唐小龙,等.改良BISAP评分系统的建立及其在重症急性胰腺炎早期诊断和预后评估中的意义[J].临床肝胆病杂志,2023,39(10):2432-2442. [6] 蒋梦可,陆宗庆,周伍明,等.1990-2019年中国胰腺炎疾病负担分析[J].中国循证医学杂志,2022,22(8):869-875. [7] 郭芳,董肖肖,马学学,等.急性胰腺炎患者甲状腺功能指标与血清内脂素的相关性分析[J].中华地方病学杂志,2021,40(8):660-663. [8] Foglio E,Pellegrini L,Russo MA,et al.HMGB1-mediated activation of the inflammatory-reparative response following myocardial infarction[J].Cells,2022,11(2):216. [9] Al-Ani Z,Ko J,Petrov MS.Intra-pancreatic fat deposition across the pancreatitis spectrum and the influence of gut hormones[J].Dig Liver Dis,2023,5(8):1081-1090. [10] 谢敏,吕睿,肖红娟,等.重症急性胰腺炎患者并发腹腔感染病原菌和sRAGE、Ghrelin与MCP-1水平及其预测价值[J].中华医院感染学杂志,2024,34(11):1697-1701.
2025, Vol. 31 
冀公网安备13080202000786号